Median Technologies announced the formation of their Clinical Advisory Board (CAB) for iBiopsy® Lung Cancer Screening. This group of world class physicians brings comprehensive expertise in the space of Lung Cancer Screening to guide Median in the development of iBiopsy® LCS AI/ML tech-based CADe/CADx SaMD (software as medical device), which detects and characterizes lung cancer nodules in high risk populations, ultimately aimed at improving patient outcomes as well as clinical workflows. Introducing the members of Clinical Advisory Board for Lung Cancer Screening (in alphabetical order): Philippe Grenier- rofessor, Thoracic Radiologist and Head of the Artificial Intelligence project, Hopital Foch, Suresnes (France), Francesco Grossi- Director of the Division of Medical Oncology and Associate Professor at the University of Insubria, Varese (Italy), Luis Seijo Maceiras- Director of Pneumology Department – Clinica Universidad de Navarra, Madrid (Spain).

Carey Thomso- Chair, Department of Medicine and Director, Multidisciplinary Thoracic Oncology and Lung Cancer Screening Program, Mount Auburn Hospital/Beth Israel Lahey Health, Cambridge, Massachusetts (United States) - Associate Professor of Medicine at Harvard Medical School, Boston, Massachussets (United States). Anil Vachani- Director of Clinical Research, Section of Interventional Pulmonary and Thoracic Oncology, Penn Medicine, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia (United States). David Yankelevitz- Professor of Radiology and Director of the Lung Biopsy Service at the Icahn School of Medicine, Mount Sinai, New York City (USA).

Javier Zulueta- Senior Faculty and Chief of the Division of Medicine (Pulmonary, Critical Care and Sleep Medicine) at Mount Sinai Morningside, Professor of Medicine, Icahn School of Medicine, Mount Sinai, New York City (USA).